[SCHEDULE 13G/A] Bio-Techne Corp. SEC Filing

Rhea-AI Filing Summary

Bio-Techne Corp is reported to have a material passive investor position: T. Rowe Price Associates, Inc. discloses beneficial ownership of 8,848,150 shares of common stock, representing 5.6% of the class. The filing shows sole voting power for 8,375,015 shares and sole dispositive power for 8,732,036 shares, with no shared voting or dispositive powers. In plain terms, T. Rowe Price can vote and direct the sale of most of these shares without sharing those rights.

T. Rowe Price identifies itself as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing does not report group affiliations or additional transactions in this statement.

Insights

Financial Analyst

TL;DR T. Rowe Price discloses a meaningful passive stake of 5.6% (8.85M shares) in Bio-Techne with primary voting and dispositive control.

The position reported is material by common thresholds for disclosure because it exceeds 5% of the class. The breakdown shows slight differences between shares with voting authority (8,375,015) and shares with dispositive authority (8,732,036), indicating typical portfolio and custodial recordkeeping effects rather than shared control. Classification as an investment adviser and the certification that holdings are in the ordinary course suggest a passive, non-control intent. For investors, this is a notable institutional holding but not an announced strategic change or control action.

Corporate Governance Expert

TL;DR A 5.6% stake by a major adviser is material but the filing affirms passive ownership with no group or shared power indicated.

The filing explicitly states there are no shared voting or dispositive powers and Item responses show no group affiliation, which reduces immediate governance concerns about a coordinated activism effort. The certification language that holdings were not acquired to influence control further supports a passive posture. While the stake is large enough to attract attention from governance observers, the document contains no indications of director nominations, proxy contests, or coalition formation.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

BIO-TECHNE CORP

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

09073M104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09073M104

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,375,015.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,732,036.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,848,150.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BIO-TECHNE CORP
(b)	Address of issuer's principal executive offices: 614 MCKINLEY PL N E, MINNEAPOLIS, MN, 55413
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 09073M104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8848150
(b)	Percent of class: 5.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8375015
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8732036
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2025

FAQ

Who filed the Schedule 13G/A for Bio-Techne (TECH)?

T. Rowe Price Associates, Inc. filed the Schedule 13G/A as the reporting person.

How many Bio-Techne shares does T. Rowe Price report owning?

8,848,150 shares are reported as beneficially owned by T. Rowe Price.

What percentage of Bio-Techne does T. Rowe Price own?

The filing reports ownership of 5.6% of the outstanding class of common stock.

What voting and dispositive powers does T. Rowe Price report?

The filing shows sole voting power for 8,375,015 shares and sole dispositive power for 8,732,036 shares; no shared voting or dispositive powers are reported.

Does the filing indicate T. Rowe Price intends to influence control of Bio-Techne?

No. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Does the filing report any group or coordinated ownership with others?

No. Item responses indicate no group affiliation and related questions are marked Not Applicable.